| Literature DB >> 30073757 |
Zhengke Zhi1,2, Hairong Zhu3, Xiaofeng Lv1,2, Changgui Lu1,2, Yang Li1,2, Feng Wu1,2, Lingling Zhou1,2, Hongxing Li1,2, Weibing Tang1,2.
Abstract
HSCR (Hirschsprung's disease) is a serious congenital defect, and the aetiology of it remains unclear. Many studies have highlighted the significant roles of intronic miRNAs and their host genes in various disease, few was mentioned in HSCR although. In this study, miR-483-3p along with its host gene IGF2 (Insulin-like growth factor 2) was found down-regulated in 60 HSCR aganglionic colon tissues compared with 60 normal controls. FHL1 (Four and a half LIM domains 1) was determined as a target gene of miR-483-3p via dual-luciferase reporter assay, and its expression was at a higher level in HSCR tissues. Here, we study cell migration and proliferation in human 293T and SH-SY5Y cell lines by performing Transwell and CCK8 assays. In conclusion, the knockdown of miR-483-3p and IGF2 both suppressed cell migration and proliferation, while the loss of FHL1 leads to opposite outcome. Furthermore, miR-483-3p mimics could rescue the negative effects on cell proliferation and migration caused by silencing IGF2, while the FHL1 siRNA may inverse the function of miR-483-3p inhibitor. This study revealed that miR-483-3p derived from IGF2 was associated with Hirschsprung's disease by targeting FHL1 and may provide a new pathway to understand the aetiology of HSCR.Entities:
Keywords: Hirschsprung's disease; four and a half LIM domains 1; gene regulation; insulin-like growth factor 2; miR-483-3p
Mesh:
Substances:
Year: 2018 PMID: 30073757 PMCID: PMC6156468 DOI: 10.1111/jcmm.13756
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Figure 1Down‐regulation of miR‐483‐3p in HSCR patients. A, The expression of miR‐483‐3p was detected in HSCR patient colon tissues (n = 60) and controls (n = 60). Data are presented as a box plot of the median and range of log‐transformed relative expression level. (*P < 0.05) B,C, The cellular function of miR‐483‐3p was verified in 293T and SH‐SY5Y cells transfected with miR‐483‐3p inhibitor. Migrated cells were then coloured with violet crystal and counted. The relative quantity of migrated cells is presented as a percentage of total cells. (**P < 0.05; ***P < 0.05) Absorbance at 450 nm is presented as mean ± SE (***P < 0.05; ***P < 0.05)
Figure 2IGF2 is the host gene of miR‐483‐3p. A,The mRNA and protein expression levels of IGF2 were lower in HSCR tissues than controls determined by qRT‐PCR and Western blot. (*P < 0.05) B, The 293T and SH‐SY5Y cells were transfected with IGF2 siRNA, and then, the expression of miR‐483‐3p was reduced in both cell lines. (***P < 0.05) C, Co‐transfection of miR‐483‐3p mimics partially rescued the IGF2 siRNA‐mediated decrease in cell migration (***P < 0.05) and proliferation (**P < 0.05). Absorbance at 450 nm was presented as mean ± SE. *means significant difference (P < .05)
Figure 3FHL1 is a downstream target of miR‐483‐3p. A, FHL1 was found up‐regulated in HSCR patients at both mRNA and protein levels. (*P < 0.05) B, The mRNA and protein expression of FHL1 were determined by qRT‐PCR and Western blot after transfected with miR‐483‐inhibitor in 293T and SH‐SY5Y cells. (**P < 0.05) C, Bottom: Sequence alignment of human miR‐483‐3p with 3′‐UTR of FHL1. Mutations in the 3′‐UTR of FHL1. TOP: The firefly luciferase activity in 293T and SH‐SY5Y cells after co‐transfection with reporter construct and miR‐483‐3p mimics (***P < 0.05; **P < 0.05)
Figure 4miR‐483‐3p effect on cell migration and proliferation was mediated by FHL1 in HSCR. A, The cell migration (***P < 0.05) and proliferation (**P < 0.05) in 293T/SH‐SY5Y cell lines transfected with FHL1 siRNA were improved than controls. B, FHL1 siRNA could partly reverse cell migration (***P < 0.05) and proliferation (***P < 0.05) in 293T and SH‐SY5Y cell lines transfected with miR‐483‐3p inhibitor. Absorbance at 450 nm was presented as mean ± SE. *means significant difference (P < .05). All results were presented as mean ± SE. *means significant difference (P < .05)